6640--LAB - Immunochemistry (IHC) Stain system CPK

The Department of Veterans Affairs, through Network Contracting Office 2, intends to award a sole-source contract to Roche Diagnostics Corporation for proprietary reagent kits and consumables compatible with VA-owned Roche Benchmark Ultra Plus immunohistochemistry instruments. This action is justified under FAR 6.302-1 due to the technical exclusivity of the reagents, as no alternative suppliers can provide products that function with the existing VA equipment. The solicitation, identified by number 36C24226Q0827, was posted on July 22, 2026, with responses due by July 30, 2026, at 10:00 a.m. Eastern Time, submitted exclusively via email to the Contracting Officer, Aleta Jennette. The contract is for laboratory reagents essential to ongoing diagnostic operations, primarily at the James J. Peters VA Medical Center in Bronx, NY, though the final place of performance remains TBD. No competitive solicitation exists, and therefore no formal evaluation factors, pricing details, line items, or contract value have been established. The procurement is non-competitive, with no set-asides for small or socioeconomic businesses, and no socioeconomic certifications or UEI/CAGE codes for the vendor are provided. Packaging, marking, preservation, inspection, acceptance criteria, and invoicing methods are not specified, with assumed compliance to standard commercial practices for laboratory reagents. Contract administration oversight is limited to the Contracting Officer, with no designated COR, COTR, or PCO identified. The contracting office is located in Albany, NY, but administrative and performance functions are centered at the Bronx facility. No FAR clauses, special requirements, or representations from the offeror are included, as the document serves solely as a market research notice indicating intent to award without requiring formal proposals, quotes, or submissions other than expressions of interest. The acquisition is driven entirely by proprietary compatibility, with no alternatives available, rendering traditional contract elements such as pricing, delivery schedules, or payment terms unnecessary at this preliminary stage.